# Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

> **NCT03775928** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 80 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT03775928
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-18
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03775928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03775928, "Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03775928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*